Title:
DIAGNOSIS OF IMMUNITY REDUCTION THROUGH INTESTINAL MICROFLORA ANALYSIS OF STOMACH CANCER PATIENTS, AND THERAGNOSTIC COMPOSITION USING INTESTINAL MICROFLORA
Document Type and Number:
WIPO Patent Application WO/2023/140721
Kind Code:
A1
Abstract:
The present invention relates to the diagnosis of immunity reduction through intestinal microflora analysis of stomach cancer patients, and a theragnostic composition using intestinal microflora. It has been identified that novel compound SD217 of the present invention specifically kills stomach cancer cells and effectively inhibits the expression of PD-L1, which is a surface protein expressed by stomach cancer cells in order to evade immune responses of the human body, and thus kills stomach cancer cells. In addition, it has been identified that: tumor size is suppressed in a stomach cancer tumor animal model; intestinal microflora diversity decreases in stomach cancer patients and the composition ratio of the intestinal microflora differs from those of healthy adults and benign tumor patients; immune function declines in stomach cancer patient groups and immune function of patients declines as the stomach cancer progresses; PD-L1 and IL-10, which increase because of reduced immunity, are effectively inhibited when macrophages derived from patients are treated with a (Faecalibacterium prausnitzii strain, which has been identified to be reduced in stomach cancer patient groups, and butyrate, which is a metabolite thereof; cell killing is effectively induced when a stomach cancer cell line is treated with a Faecalibacterium prausnitzii strain and butyrate, which is a metabolite thereof; and a stomach cancer avatar animal model in which the immune status of patients is reflected and into which a stomach cancer cell line is transplanted, butanoic acid inhibits tumor growth and reduces the expression of tumor markers and immunity reduction markers. Therefore, intestinal microflora dysbiosis and reduced immunity in stomach cancer patient groups are diagnosed such that the effects of increased immunity and intestinal microflora recovery according to the treatment of an active ingredient of the present invention have been identified, and thus it has been identified that immune anticancer drugs and individual personalized medicine can be implemented.
Inventors:
SONG KYO YOUNG (KR)
CHO MI LA (KR)
JHUN JOO YEON (KR)
JUNG YOON JU (KR)
KIM SOJUNG (KR)
LEE SEUNG YOON (KR)
WOO JIN SEOK (KR)
LEE KUN HEE (KR)
CHO MI LA (KR)
JHUN JOO YEON (KR)
JUNG YOON JU (KR)
KIM SOJUNG (KR)
LEE SEUNG YOON (KR)
WOO JIN SEOK (KR)
LEE KUN HEE (KR)
Application Number:
PCT/KR2023/001123
Publication Date:
July 27, 2023
Filing Date:
January 25, 2023
Export Citation:
Assignee:
CATHOLIC UNIV KOREA IND ACADEMIC COOPERATION FOUNDATION (KR)
International Classes:
A61K31/19; A23L33/10; A23L33/135; A61K31/155; A61K35/74; A61P35/00
Foreign References:
| KR20150022731A | 2015-03-04 | |||
| KR20190061042A | 2019-06-04 | |||
| KR20210018793A | 2021-02-18 | |||
| KR20210138410A | 2021-11-19 |
Other References:
OHUE YOSHIHIRO, NISHIKAWA HIROYOSHI: "Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?", CANCER SCIENCE, JAPANESE CANCER ASSOCIATION, TOKYO, JP, vol. 110, no. 7, 1 July 2019 (2019-07-01), JP , pages 2080 - 2089, XP093080038, ISSN: 1347-9032, DOI: 10.1111/cas.14069
Attorney, Agent or Firm:
WIE, Byoung Gap (KR)
Download PDF: